At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,181 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Treatment With Klacid SR in Patients With Acute Tracheitis, Tracheobronchitis and Bronchitis, Acute Exacerbation of Chronic Bronchitis or Mild Community-acquired Bronchopneumonia in Common Clinical Practice in the Slovak Republic
In Brief
An observational study for Tracheitis and 4 related conditions. Completed, enrolled 3,181 participants across 158 sites.
Detailed Summary
The aim of this post-marketing observational study (PMOS) is to describe the relief of symptoms, tolerability and compliance of treatment with Klacid®SR in a dose 1000 mg once daily in patients with lower respiratory tract infection or in patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsTracheitis, Tracheobronchitis, Bronchitis, Chronic Bronchitis, Community-acquired Pneumonia
CountriesSlovakia
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedApr 2010
Primary CompletionJul 2010
TodayJul 2026
First PostedApr 21, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 16.2 years ago